UNC Lineberger Comprehensive Cancer Center
unclineberger.orgTotal trials
409
Active
120
Phase 3
1
Total enrollment
117,754
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 76 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Fludarabine | — | — | — | 13 | |||
| Cyclophosphamide | — | — | — | 14 | |||
| Pembrolizumab | — | — | — | 12 | |||
| Bendamustine | — | — | — | 6 | |||
| Cisplatin | — | — | — | — | 11 | ||
| Dexamethasone | — | — | — | — | — | 4 | |
| ATLCAR.CD30 cells | — | — | — | — | 3 | ||
| Durvalumab | — | — | — | — | 3 | ||
| Isatuximab | — | — | — | — | — | 2 | |
| XL092 | — | — | — | — | 2 | ||
| Tirzepatide | — | — | — | — | 2 | ||
| Carboplatin | — | — | — | — | 15 | ||
| oxaliplatin | — | — | — | — | 5 | ||
| Rituximab | — | — | — | — | 4 | ||
| Lenalidomide | — | — | — | — | 3 | ||
| Nab-paclitaxel | — | — | — | — | — | 3 | |
| Leucovorin | — | — | — | — | 3 | ||
| Erlotinib | — | — | — | — | — | 3 | |
| Entinostat | — | — | — | — | 3 | ||
| etoposide | — | — | — | — | 2 | ||
| FOLFIRINOX | — | — | — | — | — | 2 | |
| Memantine | — | — | — | — | — | 2 | |
| Gemcitabine | — | — | — | — | — | 2 | |
| CHEP | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Cell | — | — | — | — | — | 1 | |
| SERD* + abemaciclib | — | — | — | — | — | 1 | |
| SERD* + everolimus | — | — | — | — | — | 1 | |
| SERD* + everolimus or capecitabine | — | — | — | — | — | 1 | |
| SOC | — | — | — | — | — | 1 | |
| Antiandrogen | — | — | — | — | — | 1 | |
| Neoadjuvant Pembrolizumab | — | — | — | — | — | 1 | |
| Olaparib | — | — | — | — | — | 1 | |
| Cell Therapy | — | — | — | — | — | 1 | |
| contrast agent perflutren lipid | — | — | — | — | — | 1 | |
| Irinotecan Hydrochloride | — | — | — | — | — | 1 | |
| 5-FU | — | — | — | — | — | 1 | |
| tamoxifen, anastrozole, exemestane, letrozole, fulvestrant, toremifene | — | — | — | — | — | 1 | |
| Acalabrutinib | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 |
36 more active programs hidden
Next readouts
- 2021-01-15
- 2022-02-02
- 2023-12-15
- 2024-03-25
- 2024-07-01
- 2024-08-30
- 2024-10-16
- 2024-12-19
- 2025-04-01
- 2025-05-14
Top conditions
- Breast Cancer66
- Cancer28
- Lymphoma17
- Lung Cancer17
- Colorectal Cancer15
- Bladder Cancer14
- Prostate Cancer14
- Multiple Myeloma12
Frequently asked questions about UNC Lineberger Comprehensive Cancer Center
- How many clinical trials does UNC Lineberger Comprehensive Cancer Center have on ClinicalTrials.gov?
- UNC Lineberger Comprehensive Cancer Center is listed as the lead sponsor on 409 clinical trials in ClinicalTrials.gov, 120 of which are currently active (recruiting, enrolling, or ongoing).
- How many of UNC Lineberger Comprehensive Cancer Center's trials are in Phase 3?
- 1 of UNC Lineberger Comprehensive Cancer Center's trials are in Phase 3, spread across 76 active drug programs.
- What therapeutic areas does UNC Lineberger Comprehensive Cancer Center focus on?
- UNC Lineberger Comprehensive Cancer Center's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Lymphoma, Lung Cancer, Colorectal Cancer.
- When are UNC Lineberger Comprehensive Cancer Center's next clinical trial readouts?
- UNC Lineberger Comprehensive Cancer Center has 10 upcoming primary-completion readouts tracked here; the soonest is “Administration of T Lymphocytes for Prevention of Relapse of Lymphomas”, expected around 2021-01-15.